ARCHIVEScience of Understanding
In September 2019, Camp + King created a compelling brand advertising campaign for NorthShore...
Hemlibra Turns Bloody Mary Into a Hemophilia Education Moment
Hemlibra's 'Not So Bloody Mary' is a 2024 integrated healthcare campaign created by ad agency 21GRAMS for Genentech's Hemlibra brand in the United States, using nine short social videos and a mirror filter mechanic to recast the horror character Bloody Mary as a friendly Midwestern mother who explains the hemophilia A treatment to patients in an approachable, stigma-reducing narrative.
Published in the United States in January 2024 and launched publicly on Halloween, the campaign arrived with a budget of $265,000, as documented by 21GRAMS. Its central mechanic was a social-media mirror filter that invited users to summon the 'Not So Bloody Mary' character by saying her name three times — a direct inversion of the original folkloric ritual. This interaction design transformed a culturally loaded fear symbol into a patient-friendly spokesperson, a creative pivot that sits at the intersection of entertainment and pharmaceutical education. The campaign contains one primary media asset, supported by the nine short-form social videos that formed the backbone of its distribution strategy.
The geographic focus remained squarely on the United States market, where Genentech holds responsibility for Hemlibra's commercialization, with Roche marketing the product globally. The campaign represents a deliberate shift by Genentech and 21GRAMS toward entertainment-led, platform-native education targeting younger people living with hemophilia A. By anchoring the launch to Halloween, the creative team ensured cultural relevance and maximum receptivity to the horror-genre framing, turning an annual cultural moment into a pharmaceutical narrative opportunity. The Clapboard Score for this campaign is 63 out of 100.
Hemophilia A is the most prevalent form of hemophilia. The condition's name and the visible nature of bleeding disorders carry an inherent cultural weight that can generate anxiety among newly diagnosed patients and their families, making straightforward clinical communication insufficient for building trust or encouraging treatment conversations.
21GRAMS identified horror-film iconography — specifically the Bloody Mary legend, with creative references drawing from the tradition of films such as Child's Play and The Texas Chainsaw Massacre — as a vehicle for confronting and defusing that fear rather than avoiding it. The strategic logic is precise: by occupying the exact cultural space where fear of blood is most theatrically expressed, the campaign reframes Hemlibra not as a reminder of the condition's dangers but as the force that neutralizes them. The 'Not So Bloody Mary' character's Midwestern-mother persona signals safety, domesticity, and reliability — attributes directly opposed to the horror archetype she displaces.
In the United States, the hemophilia treatment market operates within a competitive pharmaceutical landscape where Hemlibra competes against established factor replacement therapies and emerging gene therapy candidates. The hemophilia A segment represented approximately $11.14 billion of the global hemophilia market in 2024, according to Grand View Research, underscoring the commercial stakes of patient engagement in this category. The global hemophilia market is projected to grow at a compound annual growth rate of 6.9 percent from 2025 through 2030, according to Grand View Research, reflecting sustained investment in treatment innovation and patient education across markets including the United States.
Platform-native execution — deploying a social-media mirror filter alongside short-form video — reflects a documented shift within the health industry toward meeting patients on consumer entertainment platforms rather than relying exclusively on clinical or professional channels, as reported by MM&M Online. This approach positions the campaign against more conventional pharmaceutical advertising peers that continue to rely on direct-to-consumer broadcast formats.
Production credits for the 'Not So Bloody Mary' campaign are not publicly documented. The creative execution is nonetheless distinctive in its structural discipline and platform specificity, deploying nine short social videos alongside a bespoke mirror filter mechanic to deliver the campaign's narrative payload across the United States.
The mirror filter design is the campaign's most technically and conceptually precise element. Users activate the 'Not So Bloody Mary' character by repeating her name three times — a mechanic drawn directly from the source legend — which generates participation through a ritual users already know. The inversion is immediate and legible: the figure who appears is not threatening but maternal and explanatory. This single interaction mechanic transforms passive content consumption into an active brand experience, a meaningful distinction in the health industry where patient engagement depth correlates with treatment consideration.
The nine short-form videos function as a modular narrative system. Each unit can operate as a standalone touchpoint or as part of a sequential viewing experience, a format architecture well suited to social-media distribution where viewing order cannot be controlled. The horror-genre visual language — implied through framing, lighting, and the folkloric character concept — provides aesthetic coherence across the asset set without requiring a single long-form viewing commitment from the audience.
The decision to launch on Halloween is a production and scheduling choice with strategic consequences. It ensured that the horror-genre creative registered as culturally fluent rather than jarring, and it gave the campaign earned-media potential at a moment when horror-adjacent content achieves its highest organic reach across social platforms. Within the pharmaceutical industry, timing a campaign launch to a cultural calendar event of this specificity is comparatively rare, and it reflects the entertainment-led sensibility that 21GRAMS brought to this Genentech brief.
'Not So Bloody Mary' received a Gold award in the Use of Data and Analytics 2023 category at the MM&M Awards, as reported by MM&M Online. This recognition places the campaign among the recognized performers in pharmaceutical marketing craft in the United States for that award cycle.
The campaign was produced for $265,000, as documented by 21GRAMS. For a multi-format integrated effort comprising nine short social videos and a bespoke interactive mirror filter, this budget reflects efficient production management and a deliberate prioritization of creative concept over production scale. In the context of the pharmaceutical industry, where television-led direct-to-consumer campaigns routinely require multiples of this investment, the 'Not So Bloody Mary' budget signals a platform-native, social-first resource allocation.
No verified viewership, engagement rate, or patient-reach metrics for the campaign are publicly available beyond the 731 views recorded on the YouTube asset. Structural analysis, however, supports a reasonable assessment of the campaign's effectiveness as an awareness and education instrument. The mirror filter mechanic creates measurable participation events — each activation represents an intentional user action rather than a passive impression. The Halloween launch timing maximized contextual relevance for horror-adjacent content. And the Gold MM&M recognition, as reported by MM&M Online, confirms peer and industry validation of the campaign's strategic and executional quality within the health and pharmaceutical industries. Taken together, these factors suggest a campaign that achieved more engagement depth per dollar than its modest budget figure might initially imply.
'Not So Bloody Mary' is a 2024 integrated healthcare campaign for Hemlibra created by 21GRAMS in the United States. It recast the horror legend Bloody Mary as a friendly Midwestern mother who explains hemophilia A treatment through nine short social videos and an interactive mirror filter launched on Halloween with a $265,000 budget.
Ad agency 21GRAMS created the campaign for Genentech's Hemlibra brand. Genentech manages Hemlibra's commercialization in the United States, while Roche markets the product globally. The campaign was published in the United States in January 2024, following its Halloween public launch, and was recognized with a Gold MM&M award, as reported by MM&M Online.
The campaign won Gold in the Use of Data and Analytics 2023 category at the MM&M Awards, as reported by MM&M Online. This award recognized the campaign's performance within the pharmaceutical and health industries in the United States. The campaign was produced by 21GRAMS for Genentech's Hemlibra brand with a documented budget of $265,000.
Users activated the social-media mirror filter by saying the character's name three times, mirroring the original Bloody Mary legend. The character who appeared was reimagined as a reassuring Midwestern mother rather than a horror figure. This interaction mechanic turned a known cultural ritual into a patient-friendly brand engagement experience for Hemlibra in the United States.
The campaign was produced for $265,000, as documented by 21GRAMS. This budget covered nine short social videos and a bespoke interactive mirror filter distributed across social platforms in the United States. For a multi-format integrated pharmaceutical campaign, this figure reflects a platform-native production strategy prioritizing creative concept over large-scale production spend.
21GRAMS used horror-film iconography to confront and defuse the fear and stigma surrounding bleeding disorders directly. By recasting Bloody Mary as a non-threatening maternal figure, the campaign reframed Hemlibra as a stabilizing force rather than a reminder of the condition's risks. The Halloween launch timing reinforced the cultural fluency of this creative strategy in the United States.
.webp)
Creative Collaboration Platform: The Backbone of Modern Creative WorkWhat is a creative collaboration platform?Clapboard defines a creative collaboration platform as the operational core for today’s distributed creative teams. This is not a collection of digital collaboration tools stitched together; Clapboard’s system
Understanding the Creative Production MarketplaceWhat is a Creative Production Marketplace?Clapboard defines a creative production marketplace as a structured ecosystem where brands, agencies, and production talent converge to execute video, advertising, and branded content at scale. Unlike the legacy agency or freelanREAD FULL ARTICLE
The Urgent Need for a Creative Production Operating SystemWhy Traditional Creative Production Models Break DownClapboard sees the creative production landscape shifting under pressure. Content velocity is no longer a buzzword—it’s a mandate. Modern advertising demands relentless output across dozens of channels, each wREAD FULL ARTICLE
